A comparison between Bromocriptine and Selegiline in treatment of Parkinsons disease
Background and Objective: Parkinson is a common disease that caused by degeneration of nigrostriatal dopaminergic pathways. Drug therapy can prevent movement disorders in patients and so they can do independently their daily activities. Many drugs are used for treatment for this disease. This study...
Guardado en:
Autores principales: | A Ahmadi Ahangar, SAR Sadraei Mousavi |
---|---|
Formato: | article |
Lenguaje: | EN FA |
Publicado: |
Babol University of Medical Sciences
2002
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e0dce7db8d0d468cbc7fe0c6d59d79af |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
por: Werner Poewe, et al.
Publicado: (2010) -
Levodopa en la enfermedad de Parkinson: ¿Qué hemos aprendido?
por: Juri C,Carlos, et al.
Publicado: (2006) -
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease
por: Daniel D Truong
Publicado: (2009) -
Síndrome neuroléptico maligno-like como complicación en enfermedad de Parkinson: Desenlace fatal. Reporte de un caso y revisión de la literatura
por: Salinas S,Carlos, et al.
Publicado: (2014) -
Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via MA
Publicado: (2010)